Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Cost-effectiveness analysis and budget impact model of Lipoprotein (a) testing in Portuguese patients with atherosclerotic cardiovascular disease in secondary prevention
Session:
SESSÃO DE POSTERS 36 - TUDO SOBRE LÍPIDOS
Speaker:
Sara Monge
Congress:
CPC 2025
Topic:
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
Theme:
34. Public Health and Health Economics
Subtheme:
34.3 Health Economics
Session Type:
Cartazes
FP Number:
---
Authors:
Sara Monge; Joana Gomes da Costa; César Ferreira
Abstract
<p style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Arial,sans-serif"><strong><span style="font-size:11.0pt">OBJECTIVES:</span></strong><span style="font-size:11.0pt"> Elevated Lipoprotein (a) [Lp(a)] is a genetically inherited condition that has been causally associated with an increased risk for cardiovascular disease (CVD). Despite guidelines recommendation of broad Lp(a) testing, this is not implemented in real-world clinical practice. Absence of targeted therapies and economic concerns have been indicated as barriers on general Lp(a) testing. This study aims to assess the cost-effectiveness and budget impact of implementing Lp(a) testing for secondary prevention in an atherosclerotic cardiovascular disease (ASCVD) population in absence of targeted therapies, adopting the perspective of the Portuguese National Health Service (P-NHS).</span></span></span></p> <p style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Arial,sans-serif"><strong><span style="font-size:11.0pt">METHODS:</span></strong><span style="font-size:11.0pt"> A decision tree economic model followed by a Markov model and the UK Biobank’s (UKBK) predictive risk equations were used to develop the economic model. The costs and outcomes with and without Lp(a) testing were compared, with the assumption that testing might induce a behavioral change which in turn might impact other cardiovascular (CV) risk factors. </span></span></span></p> <p style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Arial,sans-serif"><strong><span style="font-size:11.0pt">RESULTS:</span></strong><span style="font-size:11.0pt"> Different scenarios were considered, and Lp(a) testing is deemed to be a cost-effective strategy in most of the scenarios with a minimal change (< 2%) in two CV risk factors. When considering a sizeable change in a single CV risk factor such as LDL-C as previously observed, Lp(a) testing is dominant. In this scenario, the budget impact model showed that testing was able to generate cost savings in a Portuguese secondary prevention ASCVD population. </span></span></span></p> <p style="text-align:justify"><span style="font-size:10pt"><span style="font-family:Arial,sans-serif"><strong><span style="font-size:11.0pt">CONCLUSIONS:</span></strong><span style="font-size:11.0pt"> Testing for Lp(a) in a secondary prevention population can be a cost-effective approach. When considering a significant change in CV risk factors, testing can be cost saving, potentially leading to relevant benefits to the P-NHS, even in the absence of target therapies. </span></span></span><span style="font-size:11.0pt"><span style="font-family:"Arial",sans-serif">Although Lp(a) testing may contribute towards an optimization of CV risk management, the unmet need of reducing Lp(a) associated CV risk remains.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site